Slowing the progress of ALS
Israel’s Neuromagen (see here previously) has received US FDA Orphan designation for its AGS-499 candidate treatment of ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease. AGS-499 has shown outstanding promise in lab tests, including using human cells.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink